Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;162(12):2126-2135.
doi: 10.1099/mic.0.000393.

Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis

Affiliations

Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis

Taylor E Woo et al. Microbiology (Reading). 2016 Dec.

Abstract

Pseudomonas aeruginosa is a major pathogen in chronic lung diseases such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (nCFB). Much of our understanding regarding infections in nCFB patients is extrapolated from findings in CF with little direct investigation on the adaptation of P. aeruginosa in nCFB patients. As such, we investigated whether the adaptation of P. aeruginosa was indeed similar between nCFB and CF. From our prospectively collected biobank, we identified 40 nCFB patients who had repeated P. aeruginosa isolates separated by ≥6 months and compared these to a control population of 28 CF patients. A total of 84 nCFB isolates [40 early (defined as the earliest isolate in the biobank) and 41 late (defined as the last available isolate in the biobank)] were compared to 83 CF isolates (39 early and 44 late). We assessed the isolates for protease, lipase and elastase production; mucoid phenotype; swarm and swim motility; biofilm production; and the presence of the lasR mutant phenotype. Overall, we observed phenotypic heterogeneity in both nCFB and CF isolates and found that P. aeruginosa adapted to the nCFB lung environment similarly to the way observed in CF isolates in terms of protease and elastase expression, motility and biofilm formation. However, significant differences between nCFB and CF isolates were observed in lipase expression, which may allude to distinct characteristics found in the lung environment of nCFB patients. We also sought to determine virulence potential over time in nCFB P. aeruginosa isolates and found that virulence decreased over time, similar to CF.

Keywords: Pseudomonas aeruginosa; cystic fibrosis; non-cystic fibrosis bronchiectasis; phenotyping; virulence factors.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Comparison of P. aeruginosa isolates between nCFB (n=84) and CF (n=83) isolates. Isolates were characterized for protease (a), elastase (b) and lipase (c) production; swim (d) and swarm (e) motility; mucoidy (f); planktonic growth (g); biomass production (h); and viable cell count in biofilm (i). Black horizontal bars represent the mean of each group. Statistical analysis of median was determined to be significant if P<0.05.
Fig. 2.
Fig. 2.
Hierarchical clustering dendrogram of phenotypic traits for nCFB and CF isolates (n=167) splits into clades I (upper) and II (lower). Average expression in each assay is represented by the black colour. Isolates with above average expression are shown in green while isolates below average are in red. nCFB isolates are all indicated by a capital B. cluster 3.0 and Java TreeView were used to build this cluster dendrogram.
Fig. 3.
Fig. 3.
Comparison of P. aeruginosa isolates from nCFB at early (n=40) and late (n=41) reference points to early (n=39) and late (n=44) CF isolates. Isolates were characterized for protease (a), elastase (b) and lipase (c) production; swim (d) and swarm (e) motility; mucoidy (f); planktonic growth (g); biomass production (h); and viable cell count in biofilm (i). Black horizontal bars represent the mean of each group. The median distribution was considered significant at P<0.05.

Similar articles

Cited by

References

    1. Al-Shirawi N., Al-Jahdall H., Al Shimemeri A.(2006). Pathogenesis, etiology and treatment of bronchiectasis. Ann Thorac Med 141–51.
    1. Barker A. F., Bardana E. J.(1988). Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 137969–978.10.1164/ajrccm/137.4.969 - DOI - PubMed
    1. Barker A. F., O'Donnell A. E., Flume P., Thompson P. J., Ruzi J. D., de Gracia J., Boersma W. G., De Soyza A., Shao L., et al. (2014). Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2738–749.10.1016/S2213-2600(14)70165-1 - DOI - PubMed
    1. Barth A. L., Pitt T. L.(1996). The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J Med Microbiol 45110–119.10.1099/00222615-45-2-110 - DOI - PubMed
    1. Bergin D. A., Hurley K., Mehta A., Cox S., Ryan D., O'Neill S. J., Reeves E. P., McElvaney N. G.(2013). Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis. J Inflamm Res 61–11.10.2147/JIR.S40081 - DOI - PMC - PubMed

LinkOut - more resources